Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | SMO | Q99835 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15424153 | 0.92 | MAPT (0.59) | MAPTTP53LMNAGAAMEN1 | |
| SCHEMBL19128931 | 0.87 | MAPT (0.44) | MAPTTP53SMOLMNAGAA | |
| SCHEMBL15424157 | 0.87 | MAPT (0.63) | MAPTTP53SMOLMNAGAA | |
| SCHEMBL15424145 | 0.87 | MEN1 (0.53) | MAPTTP53MEN1HTTKMT2A | |
| SCHEMBL12480937 | 0.87 | MAPT (0.56) | MAPTLMNAGAAMEN1HTT | |
| SCHEMBL19132331 | 0.86 | MAPT (0.56) | MAPTTP53SMOLMNAGAA | |
| SCHEMBL15424194 | 0.86 | USP28 (0.45) | MAPTTP53SMOLMNAGAA | |
| SCHEMBL19916727 | 0.85 | MAPT (0.46) | MAPTTP53SMOLMNAGAA | |
| SCHEMBL15424132 | 0.84 | MAPT (0.58) | MAPTTP53SMOLMNAGAA | |
| SCHEMBL15424184 | 0.84 | MAPT (0.41) | MAPTTP53SMOLMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9708299-B2 | Hedgehog antagonists having zinc binding moieties | GENENTECH, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20140018368-A1 | HEDGEHOG ANTAGONISTS HAVING ZINC BINDING MOIETIES | GENETECH, INC. (US) | 2014-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018368-A1 | HEDGEHOG ANTAGONISTS HAVING ZINC BINDING MOIETIES | GLI1, SHH, HDAC1 | MAPT 3245/4885TP53 471/4885SMO 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.